Acdima Pharma signed an MoU with South Korea’s SK Plasma to produce plasma-derived medicinal products in Egypt, the local press reports, without providing additional details. Medical centers treating covid-19 have been experimenting with plasma therapy, administering antibody-rich blood from recovered patients to new ones through transfusions.
More from Enterprise
The CBE is taking a tougher stance on regulation
Last summer, HSBC paid the CBE a EGP 1.4 bn…
Farmers aren’t borrowing to survive anymore — they’re investing
Medium-term loans rose more than 1k% to EGP 22.6 bn…
Why do listed companies buy back treasury shares?
Dividends are subject to a 10% withholding tax, while buybacks…
Valu gets regulatory green light to start operations in Jordan
Former Jordanian Investment Minister Mothanna Gharaibeh will serve as chairman…